Ibuprofen Improves Lung Function in Cystic Fibrosis

Also reduces need for antibiotics

FRIDAY, Oct. 19 (HealthDay News) -- High-dose ibuprofen can improve lung function and reduce the need for antibiotics in patients with cystic fibrosis, according to a review published online Oct. 17 in the Cochrane Database of Systematic Reviews.

L.C. Lands, M.D., Ph.D., and a colleague from the Cochrane Collaboration in Oxford, United Kingdom, analyzed data from four randomized or quasi-randomized controlled trials involving 287 patients (aged 5 to 39 years) with cystic fibrosis that compared oral non-steroidal anti-inflammatory drugs at any dose to placebo, for a least two months.

The researchers found that three trials examined ibuprofen and one trial examined piroxicam. The ibuprofen trials showed that the placebo group had declines in lung function (forced expiratory volume in one second, forced vital capacity). One trial showed that high-dose ibuprofen was associated with reduced intravenous antibiotic use and improved nutritional and radiological pulmonary status.

"High-dose ibuprofen can slow the progression of lung disease in people with cystic fibrosis, especially in children, and this suggests that strategies to modulate lung inflammation can be beneficial for people with cystic fibrosis," the authors conclude.

Full Text (subscription or payment may be required)

Physician's Briefing